Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

Gilead (GILD) stock and Vertex Pharma (VRTX) stock are said to be relatively immune to Trump administration's tariffs threats ...

[CNBC] Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Shares of Gilead Sciences Inc. GILD shed 2.00% to $104.21 Tuesday, on what proved to be an all-around positive trading ...